From 2002 to 2008, there were 3865 NHL patients with median age of 55 years who received CHOP/CEOP or R-CHOP/R-CEOP as front-line treatments; 2188 of these patients (median age: 52 years) received CHOP/CEOP, and 1677 patients (median age: 59 years) received R-CHOP/R-CEOP. The gene discussed is DDIT3; the disease is non-Hodgkin lymphoma.